Ashwin Kishtagari

The paper identifies mutation-specific impairments in TET2 and DNMT3A enzymatic activity as predictors of clonal hematopoiesis disease risk using methylation-based activity scores.

The paper identifies genetic drivers and clinical consequences of mosaic chromosomal alterations in 1 million individuals, linking specific aut-mCAs to disease risk and therapeutic targets.

The paper analyzes sequencing data from three cohorts to quantify cytopenia incidence and identify risk factors in clonal hematopoiesis, finding higher cytopenia rates and progression to myeloid neoplasms.

The paper introduces a cost-effective CHIP assay, identifies 101 CHIP cases in a cohort, and finds heterogeneity in clonal expansion rates by driver gene and individual.